233 related articles for article (PubMed ID: 31196060)
1. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.
Oktay E; Oflazoglu U; Varol Y; Tanriverdi O; Mermur N; Arda HU; Demir L; Keskin O; Ahmadli T; Somali I; Oztop I; Meydan N
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1201-S1208. PubMed ID: 30539871
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.
Schilsky JB; Ni A; Ahn L; Datta S; Travis WD; Kris MG; Chaft JE; Rekhtman N; Hellmann MD
Lung Cancer; 2017 Jun; 108():205-211. PubMed ID: 28625636
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.
Oktay E; Oflazoglu U; Varol Y; Tanriverdi O; Mermur N; Arda HU; Demir L; Keskin O; Ahmadli T; Somali I; Oztop I; Meydan N
J Cancer Res Ther; 2020; 16(4):737-744. PubMed ID: 32930112
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
[TBL] [Abstract][Full Text] [Related]
7. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
[TBL] [Abstract][Full Text] [Related]
8. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
[TBL] [Abstract][Full Text] [Related]
11. Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma.
Kanmaz ZD; Aras G; Tuncay E; Bahadır A; Kocatürk C; Yaşar ZA; Öz B; Özkurt CÜ; Gündoğan C; Çermik TF
Cancer Biomark; 2016; 16(3):489-98. PubMed ID: 27062706
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
13. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
14. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
15. Dual surrogate markers for rapid prediction of epidermal growth factor receptor mutation status in advanced adenocarcinoma of the lung: A novel approach in resource-limited setting.
Udupa KS; Rajendranath R; Sagar TG; Sundersingh S; Joseph T
Indian J Cancer; 2015; 52(3):266-8. PubMed ID: 26905105
[TBL] [Abstract][Full Text] [Related]
16. Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy.
Doherty MK; O'Connor E; Hannon D; O'Reilly A; Yen D; Redmond M; Grogan LM; Hennessy BT; Breathnach OS; Morris PG
Ir J Med Sci; 2019 Feb; 188(1):69-74. PubMed ID: 29948461
[TBL] [Abstract][Full Text] [Related]
17. Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases.
Rokutan-Kurata M; Yoshizawa A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Koyama M; Shigeto S; Fujimoto M; Zhang M; Morita S; Date H; Haga H
Clin Lung Cancer; 2017 Jul; 18(4):e273-e281. PubMed ID: 28065467
[TBL] [Abstract][Full Text] [Related]
18. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
[TBL] [Abstract][Full Text] [Related]
19. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Thyroid Transcription Factor-1 Expression with
Kim HS; Kim JH; Han B; Choi DR
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30736438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
